- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06793397
Un essai de phase 3 pour évaluer le CYB003 dans le trouble dépressif majeur (EMBRACE)
Une efficacité et une sécurité, phase III, étude contrôlée multicentrique, en double aveugle et randomisée comparant 2 doses actives de CYB003 et de placebo chez les participants éligibles avec un trouble dépressif majeur
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Clinical Development
- Numéro de téléphone: 877-361-4003
- E-mail: clinicaltrialsinfo@cybin.com
Lieux d'étude
-
-
-
Berlin, Allemagne, 10117
- Pas encore de recrutement
- Charité Universitaetsmedizin Berlin
-
Chercheur principal:
- Michael Koslowski
-
Contact:
- Numéro de téléphone: +49 30 450 617734
- E-mail: psychedelika-studien@charite.de
-
Frankfurt am Main, Allemagne, 60528
- Pas encore de recrutement
- University Hospital Frankfurt
-
Chercheur principal:
- Andreas Reif
-
Contact:
- Tanja Scharf
- Numéro de téléphone: +49 69 6301 86078
- E-mail: tanja.scharf@unimedizin-ffm.de
-
Mannheim, Allemagne, 68159
- Pas encore de recrutement
- Central Institute of Mental Health
-
Contact:
- Karin Bopp
- Numéro de téléphone: 3016 +49 621 1703 3163
- E-mail: Karin.bopp@zi-mannheim.de
-
Chercheur principal:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, Allemagne, 66421
- Pas encore de recrutement
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
Chercheur principal:
- Matthias Riemenschneider
-
Contact:
- Christine Geiger
- Numéro de téléphone: +49 6841 1624227
- E-mail: christine.geiger@uks.eu
-
Contact:
- Aline Freer
- Numéro de téléphone: +49 6841 1614219
- E-mail: aline.freer@uks.eu
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australie, 2050
- Recrutement
- Royal Prince Alfred Hospital
-
Chercheur principal:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, Australie, 4558
- Recrutement
- Thompson Brain & Mind Healthcare (TBMH)
-
Chercheur principal:
- Adem Can
-
Contact:
- Megan Dutton
- Numéro de téléphone: +61 4160 40977
- E-mail: mdutton@tbmh.org.au
-
Contact:
- Kristy Smyth
- Numéro de téléphone: +61 4324 41227
- E-mail: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, Australie, 3004
- Recrutement
- Ramsay Clinic
-
Chercheur principal:
- Malcolm Hopwood
-
Contact:
- Melanie Hurley
- Numéro de téléphone: 03 9279 3569
- E-mail: research.arc@ramsayhealth.com.au
-
Contact:
- Grace Monigatti
- Numéro de téléphone: 03 9279 3569
- E-mail: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, Australie, 3053
- Recrutement
- Neurocentrix Research
-
Chercheur principal:
- David Barton
-
Contact:
- Mai-Anh Bui
- Numéro de téléphone: +61 3 9546 0009
- E-mail: mai@neurocentrix.com.au
-
Contact:
- Gabriela Gonzalez
- Numéro de téléphone: +61 3 9959 8375
- E-mail: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, Australie, 3168
- Recrutement
- Monash University - Notting Hill
-
Contact:
- Olivia Lavalette
- Numéro de téléphone: 0426359494
- E-mail: olivia.lavalette@monash.edu
-
Chercheur principal:
- Paul Liknaitzky
-
-
-
-
-
Athens, Grèce, 12462
- Recrutement
- Attikon University Hospital
-
Chercheur principal:
- Nikolaos Smyrnis
-
Contact:
- Thomas Karantinos
- Numéro de téléphone: +30697466610
- E-mail: tkarantinos@gmail.com
-
Athens, Grèce, 11528
- Recrutement
- Eginitio Hospital
-
Chercheur principal:
- Nikos Stefanis
-
Contact:
- Adam Adamopoulos
- Numéro de téléphone: +30 6976032181
- E-mail: adam_adamopoulos@yahoo.com
-
Thessaloniki, Grèce, 56404
- Recrutement
- Papageorgiou General Hospital
-
Chercheur principal:
- Georgios Papazisis
-
Contact:
- Ogla Vampertzi
- Numéro de téléphone: +306973852659
- E-mail: olgatrieste@hotmail.com
-
-
-
-
-
Dublin, Irlande, D24 WK80
- Recrutement
- Sheaf House - Tallaght Adult Mental Health Service
-
Chercheur principal:
- John Kelly
-
Contact:
- Ann Connolly
- Numéro de téléphone: +353 8616 79619
- E-mail: aconnolly@crp.healthcare
-
Galway, Irlande, H91 VE03
- Recrutement
- La Nua Day Hospital Mental Health Centre
-
Contact:
- Prathyusha Nedunuru
- Numéro de téléphone: +353 874283750
- E-mail: pnedunuru@crp.healthcare
-
Chercheur principal:
- Shane McInerney
-
-
-
-
-
Bialystok, Pologne, 15-272
- Retiré
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, Pologne, 85-133
- Recrutement
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
Contact:
- Franciszek Lauchut
- Numéro de téléphone: +48 790 219 501
- E-mail: f.lachut@pro-mente.pl
-
Chercheur principal:
- Katarzyna Lachut
-
Gdansk, Pologne, 80-546
- Recrutement
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
Contact:
- Monika Drzewiecka
- Numéro de téléphone: +48 508-348-938
- E-mail: m.drzewiecka@pihouse.pl
-
Chercheur principal:
- Hanna Badzio-Jagiello
-
Gdansk, Pologne, 80-214
- Pas encore de recrutement
- UCK
-
Chercheur principal:
- Wieslaw Jerzy Cubala
-
Contact:
- Natalia Sudol
- Numéro de téléphone: +48 669 439 740
- E-mail: nat.sudol13@gmail.com
-
Warsaw, Pologne, 02-957
- Pas encore de recrutement
- Department of Pharmacology and Physiology of CNS
-
Chercheur principal:
- Justyna Holka-Pokorska
-
Warsaw, Pologne, 02-172
- Recrutement
- MTZ Clinical Research Powered by Pratia
-
Chercheur principal:
- Monika Gawlowicz
-
-
-
-
-
Cambridge, Royaume-Uni, CB1 2EU
- Recrutement
- Cambridge University Hospital NHS
-
Chercheur principal:
- Liliana Galindo
-
Contact:
- Tracy Assari
- Numéro de téléphone: +44 1223 219751
- E-mail: t.assari@nhs.net
-
Contact:
- Emma Tudor
- Numéro de téléphone: +44 1223 219751
- E-mail: Emma.tudor@cpft.nhs
-
Doncaster, Royaume-Uni, DN4 8QN
- Recrutement
- Clerkenwell Health - Doncaster
-
Chercheur principal:
- Paul Morrison
-
Contact:
- Celia Creaghan
- Numéro de téléphone: +44 7849 640886
- E-mail: ccreaghan@clerkenwellhealth.com
-
Edinburgh, Royaume-Uni, EH16 4TJ
- Pas encore de recrutement
- NHS Research Scotland
-
Chercheur principal:
- Donald MacIntyre
-
Contact:
- Carrie Wardhaugh
- Numéro de téléphone: +44 1315375867
- E-mail: carrie.wardhaugh@ed.ac.uk
-
Glasgow, Royaume-Uni, G51 4TF
- Pas encore de recrutement
- Queen Elizabeth University Hospital
-
Chercheur principal:
- Maytal Wolfe
-
Contact:
- Rebecca Baird
- E-mail: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, Royaume-Uni, L7 8XP
- Pas encore de recrutement
- Royal Liverpool Hospital
-
Contact:
- Rachel Crick
- Numéro de téléphone: +44730 861 3597
- E-mail: Rachel.Crick@merseycare.nhs.uk
-
Chercheur principal:
- Fabian Devlin
-
London, Royaume-Uni, EC2Y 8EA
- Recrutement
- St Pancras Clinical Research
-
Chercheur principal:
- Martin Johnson
-
Contact:
- Participant Engagement Team
- Numéro de téléphone: +44 20 38651142
- E-mail: studyinformation@stpancrasclinical.com
-
London, Royaume-Uni, W1U 6RP
- Recrutement
- Clerkenwell Health - Baker Street
-
Chercheur principal:
- Alishah Suleman
-
Contact:
- Takunda Gwenhure
- Numéro de téléphone: +44 2038974867
- E-mail: tgwenhure@clerkenwellhealth.com
-
Contact:
- Victor Jardim
- Numéro de téléphone: +44 2038974867
- E-mail: vjardim@clerkenwellhealth.com
-
London, Royaume-Uni, W1G9 RU
- Recrutement
- Re:Cognition Health
-
Chercheur principal:
- Dimitrios Paschos
-
Contact:
- Numéro de téléphone: +44-0800-802-1030
-
London, Royaume-Uni, SE5 9RS
- Recrutement
- King's College London
-
Contact:
- Catheine Bird
- E-mail: catherine.bird@kcl.ac.uk
-
Contact:
- Paige Seath
- E-mail: paige.seath@kcl.ac.uk
-
Chercheur principal:
- James Rucker
-
London, Royaume-Uni, W1G 8DR
- Retiré
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, Royaume-Uni, NE4 5PL
- Recrutement
- Edwardson Building - Campus for Ageing and Vitality
-
Contact:
- Victoria Wilson
- Numéro de téléphone: +44 191 246 8647
- E-mail: victoria.wilson3@cntw.nhs.uk
-
Contact:
- Rebecca Woodhouse
- E-mail: Rebecca.Woodhouse@cntw.nhs.uk
-
Chercheur principal:
- Mourad Wahba
-
Reading, Royaume-Uni, RG7 8PA
- Recrutement
- Ascend Clinical Research
-
Chercheur principal:
- Pamela Walters
-
Contact:
- Alexandra Diaz
- Numéro de téléphone: +44 118 3045905
- E-mail: adiaz@ascendclinical-research.com
-
Sheffield, Royaume-Uni, S4 7QQ
- Recrutement
- Sheffield Health and Social Care NHS Foundation Trust
-
Chercheur principal:
- William Gann
-
Contact:
- Mishell Cunningham
- Numéro de téléphone: +44 114 271 6731
- E-mail: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
-
-
-
Prague, Tchéquie
- Pas encore de recrutement
- Institute of neuropsychiatric Care (INEP)
-
Chercheur principal:
- Alexander Nawka
-
Contact:
- Numéro de téléphone: +420 222 201 020
- E-mail: info@inep.cz
-
Prague, Tchéquie
- Pas encore de recrutement
- Psyon s.r.o.
-
Chercheur principal:
- Tomas Palenicek
-
Contact:
- Numéro de téléphone: +420 774 401 161
- E-mail: info@psyon.cz
-
Předměstí, Tchéquie
- Pas encore de recrutement
- A-SHINE s.r.o.
-
Chercheur principal:
- Lubos Janu
-
Contact:
- Blanka Vopelková
- Numéro de téléphone: +490 777 732 244
- E-mail: blanka.vopelkova@seznam.cz
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35209
- Recrutement
- UAB Psychiatry and Behavioral Neurology
-
Contact:
- Seher Premani
- Numéro de téléphone: 205-996-1198
- E-mail: spremani@uab.edu
-
Chercheur principal:
- Peter Hendricks
-
Contact:
- Maggie Gossage
- E-mail: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, États-Unis, 85234
- Recrutement
- Lighthouse Psychiatry
-
Contact:
- Chung Trinh
- Numéro de téléphone: 435-268-5800
- E-mail: ctrinh@neosciclinicalresearch.com
-
Chercheur principal:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72204
- Retiré
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, États-Unis, 91206
- Recrutement
- Behavioral Research Specialists, LLC
-
Chercheur principal:
- Jesse Carr
-
Contact:
- Laisha Uribe
- Numéro de téléphone: 888-255-5798
- E-mail: laisha@brstrials.com
-
Imperial, California, États-Unis, 92251
- Retiré
- Sun Valley Research Center
-
Los Angeles, California, États-Unis, 90025
- Recrutement
- CalNeuro Research Group
-
Chercheur principal:
- Alexander Bystritsky
-
Contact:
- Numéro de téléphone: 310-208-7144
- E-mail: info@calneuroresearch.com
-
Los Angeles, California, États-Unis, 90025
- Recrutement
- Lipov Medical Group
-
Contact:
- Brittany Juhlmann
- Numéro de téléphone: 262-352-8835
- E-mail: brittany.juhlmann@stellacenter.com
-
Chercheur principal:
- Jacob Moussai
-
Orange, California, États-Unis, 92868
- Recrutement
- NRC Research Institute
-
Contact:
- Christian Ortiz
- Numéro de téléphone: 714-289-1100
- E-mail: cortiz@nrcresearch.com
-
Chercheur principal:
- Daniel Chueh
-
Orange, California, États-Unis, 92866
- Recrutement
- ATP Clinical Research
-
Chercheur principal:
- Gustavo Alva
-
Contact:
- Sarah Perkins
- Numéro de téléphone: 949-354-5353
- E-mail: sarahp@pnsoc.com
-
San Juan Capistrano, California, États-Unis, 92675
- Pas encore de recrutement
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
Chercheur principal:
- Neelima Kunam
-
Contact:
- Numéro de téléphone: 909-955-5865
- E-mail: research@inlandpsych.com
-
Santa Monica, California, États-Unis, 90404
- Recrutement
- Psychedelic Science Institute
-
Chercheur principal:
- Keith Heinzerling
-
Contact:
- Numéro de téléphone: 213-973-7512
- E-mail: trialadmin@psychedelicsci.com
-
Stanford, California, États-Unis, 94305
- Retiré
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06511
- Recrutement
- Yale School of Medicine - Yale Program for Psychedelic Science
-
Chercheur principal:
- Ben Kelmendi
-
Contact:
- Daidre Chamberlain
- Numéro de téléphone: 203-693-1591
- E-mail: enact@yale.edu
-
Contact:
- Terrence Ching
- Numéro de téléphone: 502-612-1127
- E-mail: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32256
- Recrutement
- CNS Healthcare
-
Contact:
- Numéro de téléphone: 904-281-5757
-
Chercheur principal:
- John Mark Joyce
-
Maitland, Florida, États-Unis, 32751
- Recrutement
- Accel Research Sites - Maitland
-
Contact:
- Numéro de téléphone: 407-644-1165
-
Chercheur principal:
- Andrea Marrafino
-
Naples, Florida, États-Unis, 34105
- Recrutement
- Aqualane Clinical Research
-
Chercheur principal:
- Matthew Baker
-
Contact:
- Rachel Novella
- Numéro de téléphone: 239-529-6780
- E-mail: Rachel@Aqualaneresearch.com
-
Tampa, Florida, États-Unis, 33634
- Recrutement
- K2 Medical Research Tampa
-
Chercheur principal:
- Kelley Wilson
-
Contact:
- Jessica Myers
- Numéro de téléphone: 352-500-5252
- E-mail: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Retiré
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, États-Unis, 30060
- Recrutement
- Psych Atlanta
-
Chercheur principal:
- Michael Banov
-
Contact:
- Numéro de téléphone: 770-422-2846
- E-mail: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Recrutement
- Rush University
-
Chercheur principal:
- Joshua Eloge
-
Contact:
- Stephanie Gutierrez
- Numéro de téléphone: 312-942-8995
- E-mail: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, États-Unis, 70006
- Retiré
- Tandem Clinical Research
-
New Orleans, Louisiana, États-Unis, 70115
- Recrutement
- Atlas Psychiatry
-
Contact:
- Milton Boresoff
- Numéro de téléphone: 504-899-1682
- E-mail: m.boresoff@atlaspsychiatry.com
-
Chercheur principal:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21224
- Retiré
- Johns Hopkins Medicine
-
Rockville, Maryland, États-Unis, 20850
- Pas encore de recrutement
- Sunstone Medical, PC
-
Contact:
- Manish Agrawal, MD
- Numéro de téléphone: 301-750-3401
- E-mail: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02116
- Recrutement
- Adams Clinical Boston
-
Chercheur principal:
- Darin Dougherty
-
Contact:
- Participant Navigators
- Numéro de téléphone: 617-404-4714
- E-mail: info@adamsclinical.com
-
Watertown, Massachusetts, États-Unis, 02472
- Recrutement
- Adams Clinical Watertown
-
Chercheur principal:
- Stephanie Ellickson
-
Contact:
- Participant Navigators
- Numéro de téléphone: 617-404-4714
- E-mail: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, États-Unis, 55347
- Recrutement
- Institute for Integrative Therapies
-
Chercheur principal:
- Manoj Doss
-
Contact:
- Sena Ostwalt
- Numéro de téléphone: 6512808774
- E-mail: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, États-Unis, 55427
- Pas encore de recrutement
- The Remedy Mental Health
-
Contact:
- Emmanuel Arhin
- Numéro de téléphone: (651) 382-9518
- E-mail: emmanuel.arhin@theremedymn.com
-
Chercheur principal:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89119
- Recrutement
- Redbird Research, LLC
-
Chercheur principal:
- Jelena Kunovac
-
Contact:
- Numéro de téléphone: 702-577-2000
- E-mail: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, États-Unis, 08755
- Recrutement
- Bio Behavioral Health
-
Contact:
- Jessica Sutton
- Numéro de téléphone: 732-244-2299
- E-mail: jessica@bbhnj.com
-
Chercheur principal:
- Ashok Patel
-
-
New York
-
New York, New York, États-Unis, 10032
- Pas encore de recrutement
- New York State Psychiatric Institute
-
Chercheur principal:
- Natalie Gukasyan
-
Contact:
- Alexandra Mackay
- Numéro de téléphone: 212-342-1424
- E-mail: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, États-Unis, 10029
- Recrutement
- Adams Clinical Harlem
-
Chercheur principal:
- Rachel Noone
-
Contact:
- Participant Navigators
- Numéro de téléphone: 917-454-3746
- E-mail: info@adamsclinical.com
-
The Bronx, New York, États-Unis, 10461
- Recrutement
- Adams Clinical Bronx
-
Chercheur principal:
- Shama Farooq
-
Contact:
- Participant Navigators
- Numéro de téléphone: 917-454-3746
- E-mail: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73112
- Retiré
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- Adams Clinical Philadelphia
-
Chercheur principal:
- Cassie Blanchard
-
Contact:
- Participant Navigators
- Numéro de téléphone: 267-376-0266
- E-mail: info@adamsclinical.com
-
Philadelphia, Pennsylvania, États-Unis, 19462
- Recrutement
- Flourish Research Philadelphia
-
Chercheur principal:
- Rachna Saralkar
-
Contact:
- Numéro de téléphone: 215-614-5606
-
-
Texas
-
Austin, Texas, États-Unis, 78737
- Retiré
- Austin Clinical Trial Partners
-
DeSoto, Texas, États-Unis, 75115
- Recrutement
- Adams Clinical Dallas
-
Chercheur principal:
- Rajinder Shiwach
-
Contact:
- Participant Navigators
- Numéro de téléphone: 469-379-2494
- E-mail: info@adamsclinical.com
-
Fort Worth, Texas, États-Unis, 76104
- Retiré
- North Texas Clinical Trials
-
Houston, Texas, États-Unis, 77046
- Recrutement
- Brain Health Consultants and TMS Center
-
Chercheur principal:
- Lauren Marangell
-
Contact:
- Numéro de téléphone: 713-489-5000
- E-mail: info@brainhealthconsultants.com
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- Flourish Research San Antonio
-
Chercheur principal:
- Parke Hedges
-
Contact:
- Xavier Martinez
- Numéro de téléphone: 237 210-949-0122
- E-mail: xmartinez@flourishresearch.com
-
Contact:
- Andrea Gomez
- Numéro de téléphone: 122 210-949-0122
- E-mail: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, États-Unis, 98201
- Pas encore de recrutement
- Core Clinical Research
-
Contact:
- Maria Golescu
- Numéro de téléphone: 425-443-9551
- E-mail: maria.golescu@ccrtrial.com
-
Chercheur principal:
- James Knutson
-
Seattle, Washington, États-Unis, 98104
- Recrutement
- Seattle Neuropsychiatric Treatment Center
-
Chercheur principal:
- Rebecca Allen
-
Contact:
- Numéro de téléphone: 5 206-467-6300
- E-mail: research@seattlentc.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Expérimental: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Comparateur placebo: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
Délai: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
Délai: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
Délai: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Délai: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Délai: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Felix Mazer, Cybin IRL Limited
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CYB003-003
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .